Trial Profile
Validation of MRI as a Sensitive Tool to Longitudinally Monitor CF Lung Disease Progression and Response to CFTR Modulator Therapy in Young Children With CF
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Oct 2023
Price :
$35
*
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 23 Oct 2023 Planned End Date changed from 31 Dec 2023 to 31 Oct 2025.
- 23 Oct 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2025.
- 29 Aug 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2023.